Cancer Advanced and Consultant Pharmacist credentialing support series – First session

Rising Demand for Specialist Pharmacy Roles

Britain's cancer services face mounting strain from an ageing population and increasing incidence of complex cases, amplifying the need for highly skilled pharmacists who can lead on medicines optimisation, prescribing, and multidisciplinary decision-making. The Royal Pharmaceutical Society's credentialing frameworks—core advanced since 2023 and consultant-level—provide formal recognition of these capabilities, bridging foundation practice to senior roles.

Momentum accelerated markedly in 2024, when total submissions across RPS post-registration schemes jumped from 78 in 2023 to 226, with the core advanced strand alone attracting 121 candidates. This reflects broader NHS efforts to embed advanced practitioners in clinical pathways, particularly in specialties like oncology where pharmacists handle high-risk systemic therapies and supportive care.

The stakes are tangible: without sufficient credentialed staff, cancer multidisciplinary teams risk bottlenecks in patient management, delayed treatments, and suboptimal medicines use, contributing to wider NHS backlogs. For pharmacists, achieving consultant-ready status unlocks eligibility for senior posts that command greater responsibility and influence, yet the rigorous assessment—requiring mapped evidence against curricula—imposes significant time and professional demands.

Tensions persist between rapid workforce upskilling and quality assurance; the 52% first-time pass rate for core advanced highlights the challenge of meeting standards, while regional skews (91% of candidates in England, often primary care) suggest uneven access or focus across sectors and nations. In oncology, where BOPA supports members through targeted series amid these shifts, the drive balances professional development against the practicalities of service delivery in an overstretched system.